BACKGROUND/ OBJECTIVES: This study assesses adherence to performance measures for acute myocardial infarction (AMI) in six Middle-Eastern countries, and its association with in-hospital mortality. Few studies have previously assessed these performance measures in the Middle East. METHODS: This cohort study followed 5813 patients with suspected AMI upon admission to discharge. Proportions of eligible participants receiving the following performance measures were calculated: medications within 24 hours of admission (aspirin and beta-blocker) and on discharge (aspirin, beta-blockers, angiotensin converting enzyme inhibitors [ACEI], and lipid-lowering therapy), reperfusion therapy, and low-density lipoprotein (LDL) cholesterol measurement. A composite adherence score was calculated. Associations between performance measures and clinical characteristics were assessed using multivariate logistic regression. RESULTS: Adherence was above 90% for aspirin, reperfusion, and lipid-lowering therapies; between 60% and 82% for beta-blockers, ACEI, statin therapy, time-to-balloon within 90 minutes, and LDL-cholesterol measurement; and 33% for time-to-needle within 30 minutes. After adjustment, factors associated with high composite performance score (>85%) included Asian ethnicity (Odds Ratio, OR=1.3; p=0.01) and history of hyperlipidemia (OR=1.4; p=0.001). Factors associated with a lower score included atypical symptoms (OR=0.6; p=0.003) and high GRACE score (OR=0.6; p<0.001). Lower in-hospital mortality was associated with provision of reperfusion therapy (OR=0.54, p=0.047) and beta-blockers within 24 hours (OR=0.33, p=0.005). CONCLUSIONS: Overall adherence was lowest among the highest-risk patients. Lower in-hospital mortality was independently associated with adherence to early performance measures, comprising observational evidence for their effectiveness in a Middle East cohort. These data provide a focus for regional quality improvement initiatives and research.
BACKGROUND/ OBJECTIVES: This study assesses adherence to performance measures for acute myocardial infarction (AMI) in six Middle-Eastern countries, and its association with in-hospital mortality. Few studies have previously assessed these performance measures in the Middle East. METHODS: This cohort study followed 5813 patients with suspected AMI upon admission to discharge. Proportions of eligible participants receiving the following performance measures were calculated: medications within 24 hours of admission (aspirin and beta-blocker) and on discharge (aspirin, beta-blockers, angiotensin converting enzyme inhibitors [ACEI], and lipid-lowering therapy), reperfusion therapy, and low-density lipoprotein (LDL) cholesterol measurement. A composite adherence score was calculated. Associations between performance measures and clinical characteristics were assessed using multivariate logistic regression. RESULTS: Adherence was above 90% for aspirin, reperfusion, and lipid-lowering therapies; between 60% and 82% for beta-blockers, ACEI, statin therapy, time-to-balloon within 90 minutes, and LDL-cholesterol measurement; and 33% for time-to-needle within 30 minutes. After adjustment, factors associated with high composite performance score (>85%) included Asian ethnicity (Odds Ratio, OR=1.3; p=0.01) and history of hyperlipidemia (OR=1.4; p=0.001). Factors associated with a lower score included atypical symptoms (OR=0.6; p=0.003) and high GRACE score (OR=0.6; p<0.001). Lower in-hospital mortality was associated with provision of reperfusion therapy (OR=0.54, p=0.047) and beta-blockers within 24 hours (OR=0.33, p=0.005). CONCLUSIONS: Overall adherence was lowest among the highest-risk patients. Lower in-hospital mortality was independently associated with adherence to early performance measures, comprising observational evidence for their effectiveness in a Middle East cohort. These data provide a focus for regional quality improvement initiatives and research.
Authors: Pedro Gabriel Melo de Barros; John Li; Christine Tremblay; Mariana Yumi Okada; Henry Sznejder; Valter Furlan; Rafael Vasconcellos Journal: Clinics (Sao Paulo) Date: 2020-08-26 Impact factor: 2.365
Authors: Pedro Gabriel Melo de Barros E Silva; Thiago Andrade Macedo; Renato D Lopes; Mariana Y Okada; Tiago Frigini; Patricia O Roveri; Rodrigo Balada; Lucas Silva de Macedo; Valter Furlan Journal: Telemed Rep Date: 2021-12-22
Authors: Haibo Zhang; Frederick A Masoudi; Jing Li; Qing Wang; Xi Li; John A Spertus; Joseph S Ross; Nihar R Desai; Harlan M Krumholz; Lixin Jiang Journal: Am Heart J Date: 2015-05-22 Impact factor: 4.749
Authors: Emily M Bucholz; Neel M Butala; Sharon-Lise T Normand; Yun Wang; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2016-05-24 Impact factor: 24.094
Authors: T B Dondo; M Hall; A D Timmis; A T Yan; P D Batin; G Oliver; O A Alabas; P Norman; J E Deanfield; K Bloor; H Hemingway; C P Gale Journal: BMJ Open Date: 2016-07-12 Impact factor: 2.692